Six cases received second-line chemotherapy, including HAIC with CPT-11 in two, HAIC as a combination

of 5-FU and CPT-11 in two, and systemic LY450139 concentration chemotherapy in two. Three cases received third-line chemotherapy, including HAIC plus S-1 oral administration in one, and systemic chemotherapy with bevacizumab in two. CR was observed in 3 of 11 patients (27%), PR in 5 (46%), and PD in 3. Two of 3 cases showing CR achieved long survival without tumor relapse. All cases showing PR and PD had tumor progression, but two cases survived over 24 months. Table 2 shows the treatment results of HAIC using CPT-11 (irinotecan) as a primary chemotherapy in 16 patients. Ten patients underwent HAIC for non-resectable CLM and Inhibitors,research,lifescience,medical 6 underwent HAIC for posthepatectomy recurrence. Seven cases received second-line chemotherapy, including HAIC with 5-FU CIA in 6, and systemic chemotherapy in 1. CR was observed in 1 of 16 patients (6%) (Figure 3), PR in 10 (63%), Inhibitors,research,lifescience,medical SD in 1 and PD in 4. One patient showing CR achieved long survival without tumor relapse. All patients except the one showing CR displayed tumor progression, but 3 cases showing PR achieved survival over Inhibitors,research,lifescience,medical 24 months. Table 3 shows treatment results for HAIC using a combination of 5-FU CIA and CPT-11 (irinotecan) as a primary chemotherapy in 9 patients. Four patients underwent HAIC for non-resectable CLM and 5 underwent

HAIC for posthepatectomy recurrence. Two of 9 cases (22%) received second-line systemic chemotherapy. CR was not observed and Inhibitors,research,lifescience,medical PR was observed in 3 patients (33%), SD in 3 and PD in 3. All patients showed tumor progression and only 1 patient showing SD survived over 24 months. Table 1 HAIC applying 5-FU-CIA as primary chemotherapy Table 2 HAIC applying Irinotecan as primary chemotherapy Figure

3 Two representative cases of complete response after HAIC. Left, pre-HAIC findings from computed tomography; right, findings at the time of complete response Table 3 HAIC applying 5-FU-CIA+Irinotecan as primary chemotherapy Table 4 shows morbidity after HAIC, with 6 patients displaying associated complications (17%). Inhibitors,research,lifescience,medical Median duration of HAIC use was 238 days. Cather occlusion was observed in 3 patients, unless port-site infection in 2 and catheter dislocation in 1. HAIC was able to be continued in 4 of these 6 cases by re-inserting or exchanging the catheter. Chemotherapy-associated complications were blood toxicity with grade 1 or 2 in 13 patients. Grade 4 leukocytopenia was observed in 2 patients (6%), one of whom died from subsequent acute respiratory distress syndrome and sepsis. Table 4 Catheter- or HAIC associated complications Figure 4 shows tumor progression-free survival after HAIC for each level of response to chemotherapy. Median survival in CR patients was 57 months and no tumor progression was seen; survival was significantly longer than that with PR (13 months, P=0.024), SD (1.7 months, P=0.012) or PD (1.5 months, P=0.016).